Primary Health Properties

At the annual general meeting shareholders approved all proposed resolutions, including the annual report for the financial year ended 31 December 2025 (99.97% in favour), the dividend policy (99.97%) and a scrip dividend (99.88%). The remuneration report was approved with 96.75%, Deloitte was reappointed as auditor with 93.90%, and the authority to issue shares was approved with 94.31%. Director re-elections received mostly high approval rates; Harry Hyman received the lowest support at 89.22%. Votes represented 63.75% of the issued share capital. » More on de.investing.com

Primary Health Properties has issued 59,473 ordinary shares at 12.5 pence each to satisfy awards under the Long Term Incentive Plan granted in 2023. The new shares will be admitted to trading on the London Stock Exchange’s Main Market from 30 March. After admission, the number of issued ordinary shares will increase to 2,595,149,224; the company holds no shares in treasury. » More on de.investing.com

Primary Health Properties reported adjusted EPS growth of 4% to 7.3 pence for 2025 and a 3% dividend increase — the 30th consecutive annual rise. The merger with Assura contributed significantly to the earnings gain, while EPRA NTA fell 4% to 99 pence. The share price dropped about 2.1% after the results; management plans to reduce LTV to 40–50% through deleveraging measures and is optimistic about 2026. » More on de.investing.com